Advanced Drug Delivery Systems Market, By Delivery Mode (Oral drug, Pulmonary drug, Transdermal drug, Parenteral drug), By Carrier Type (Liposomes, Nanoparticles, Microspheres, Monoclonal antibodies, Others), By End Users (Hospitals, Specialized clinics, Clinical Research & Development Centers), By Region - Global Analysis Forecast Till 2030

The global Advanced Drug Delivery Systems Market was worth USD 56.12 billion in 2021 and is expected to be worth around USD 220.09 billion by 2030, growing at a compound annual growth rate (CAGR) of 18.01% from 2022 to 2030.

Advanced drug delivery systems are more controlled methods of delivering the drug molecule to the desired target. These techniques are being developed to improve the therapeutic ratio of existing drugs. The development of advanced drug delivery systems is based on drug delivery at a predetermined rate and slow and targeted delivery for onsite drug release and absorption.

The ability to deliver a drug more selectively to a specific site, more accessible, more precise, less common dosing, reduced variability in systemic drug levels, absorption that is more consistent with the site and mode of action, and toxic compound reductions are all major advantages of advanced drug delivery systems over traditional systems.

Targeted Drug Delivery, Polymeric Drug Delivery, Sustained Release, Implants & IUDs, and Prodrugs are the different Advanced Drug Delivery System types. Targeted drug delivery is the process of delivering a drug directly into its intended body area to eliminate the specific toxic effect of conventional drug delivery and, as a result, reduce the amount of drug remediation for therapeutic efficacy. Prodrugs are molecules with no pharmacological activity that are converted in vivo to the active parent drug via enzymatic, chemical, or a combination of the two processes.

Market Dynamics

Drivers:

Progress in biology-related activities has created a once-in-a-lifetime opportunity to better understand the molecular causes of human illnesses and develop novel medications and biologics based on these variables.

Among the recently identified enhanced drug delivery methods are lipid, protein, and polymer technologies that improve lipid distribution in the body, limit drug degradation due to the external environment, and slow the rate of drug clearance. Because modern pharmaceuticals and biologics are more efficient with lower medication dosages, they require sophisticated drug delivery methods to achieve maximum efficacy.

Restraints:

Drug delivery challenges and product recalls are two major factors that are expected to stymie the growth of the advanced drug delivery systems market.  For instance, Ikaria, Inc. announced in August 2020 that its INOMAX DS drug-delivery systems in the United States are being voluntarily recalled due to the potential failure of a pressure switch, which may impact patient administration of INOMAX (nitric oxide) for inhalation.

Key players:

• 3M,

• Raphas Co., Ltd.,

• Abbvie Inc.,

• Alnylam Pharmaceuticals, Inc.,

• Altaris Capital Partners, Llc. (Kindeva Drug Delivery),

• Bausch Health Companies Inc. (Bausch & Lomb),

• Baxter,

• Becton,

• Dickinson And Company,

• Biogen Limited,

• Endo International Plc.,

• Boston Scientific Corporation,

• Galderma,

• Johnson & Johnson (Johnson & Johnson Vision),

• Kindeva Drug Delivery L.P,

• Micropoint Technologies Pte Ltd.,

• Nanopass,

• Novo Nordisk,

• Ocular Therapeutix, Inc.,

• Takeda Pharmaceutical Company Limited

Market Segmentation:

Advanced Drug Delivery Systems Market, By Delivery Mode      

• Oral drug delivery

• Pulmonary drug delivery

• Transdermal drug delivery

• Parenteral drug delivery

Advanced Drug Delivery Systems Market, By Carrier Type          

• Liposomes

• Nanoparticles

• Microspheres

• Monoclonal antibodies

• Others

Advanced Drug Delivery Systems Market, By End Users   

• Hospitals

• Specialized clinics

• Clinical Research & Development Centers

Advanced Drug Delivery Systems Market, By Region

• North America

• Latin America

• Europe

• Asia Pacific

• Middle East & Africa

Regional Analysis:

According to a Advanced Drug Delivery Systems Market, North America dominated the global advanced drug delivery systems market in 2021 and is expected to maintain its position during the forecast period. The region's market is being driven by an increase in R&D expenditure, an increase in the adoption of novel and improved devices, the early availability of advanced technologies, an increase in healthcare expenditure, and the presence of sophisticated healthcare infrastructure and key market participants in the United States and Canada. Abbott Laboratories and Becton, Dickinson, and Company have significant presences in the United States.

According to the global advanced drug delivery systems market forecast, Asia Pacific will experience the fastest, double-digit growth due to an increase in the region's geriatric population, an increase in the prevalence of cardiovascular diseases, an expansion in healthcare infrastructure, and an increase in medical tourism. India, Malaysia, Singapore, and Thailand are prominent medical tourism destinations in Asia Pacific, according to the Organization for Economic Cooperation and Development (OECD).

Scope of the Report:

User

Tab Content